Dr. James Berenson helps patients understand new FDA recommendations regarding the use of lenalidomide (Revlimid) and a study from Sweden regarding increased risk of blot clots for myeloma patients. Dr. Berenson also previews the topics that he believes will be important for patients at the upcoming ASCO conference.
Tag Archives: Revlimid
James R. Berenson, MD
President and CEO - James R. Berenson, MD, Inc.
Medical & Scientific Director - Institute for Myeloma
& Bone Cancer Research (IMBCR)
Chief Executive Officer - Oncotherapeutics
Multiple myeloma (active) is the most common type plasma cell cancer. However, the following are other forms of myeloma or myeloma-related conditions:
- Monoclonal gammopathy of undetermined significance (MGUS)
- Asymptomatic (smoldering/indolent) myeloma
- solitary plasmacytoma of the bone
- Extramedullary plasmacytoma
- Light chain myeloma
- Non-secretory myeloma
- Osteosclerotic myeloma (POEMS syndrome)
- Waldenstrom macroglobulinemia
- Light chain amyloidosis
- Plasma cell leukemia
- Combined TRAF6 Targeting and Proteasome Blockade has Anti-tumor and Anti-bone Resorptive Effects March 5, 2017
- Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients March 5, 2017
- Outcomes in Multiple Myeloma Patients Evaluated March 5, 2017
- Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib March 5, 2017
- Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma March 5, 2017
- Combined TRAF6 Targeting and Proteasome Blockade has Anti-tumor and Anti-bone Resorptive Effects March 5, 2017
- The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo March 19, 2011
- Oncology CRO Oncotherapeutics Presents at ASH 2011 Annual Meeting November 23, 2011
- Understanding Myeloma News About Secondary Cancers and Clotting May 28, 2012
-
Dedication of “Determination” June 1, 2012
accelerated; elotuzumab; infusion rate; monoclonal antibody; multiple myeloma
ASCO
B-cell maturation antigen
BCMA
Biomarker
Bortezomib
bortezomib; carfilzomib; multiple myeloma; proteasome inhibitor; relapsed; refractory
Carfilzomib
Dedication
HevyLite; immunoglobulins; multiple myeloma; outcomes
IMBCR
Kyprolis
lenalidomide
monoclonal antibodies
more is not better
Multiple Myeloma
myeloma
Overall survival
Pomalyst
proteasome inhibitors
Revlimid
Secondary Cancers
TRAF6
transplant
update
May 28, 2012
0 Comments